Hintringer, K. (2011): Dasatinib (Sprycel®) for the 1st-line treatment of Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase. DSD: Horizon Scanning in Oncology 17.
|PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader|
Dasatinib, a second generation tyrosine-kinase inhibitor (TKI), reduces the proliferation of BCR-ABL positive chronic myeloid leukemia (CML) cells by inhibiting the BCR-ABL pathway. Since 2006 dasatinib is approved for 2nd-line leukaemia therapy in Europe. In October 2010, the EMA granted a positive opinion for the approval of dasatinib for the 1st-line therapy of Philadelphia-chromosome positive CML in the chronic phase (Ph+CML-CP).
The pivotal DASISION trial investigates whether dasatinib 100mg orally once daily is more effective as 1st-line therapy in Ph+ CML-CP patients than the current standard of care – imatinib 400mg orally once daily.
The results of the trial indicate that dasatinib is clinically more effective than imatinib. The confirmed complete cytogenetic response, the primary endpoint, is 77% vs. 66% (p=0.007) in the dasatinib and imatinib groups, respectively. Progression to the accelerated phase or blast crisis occurred more frequent in the control group (3.5%) compared to the dasatinib group (1.9%). Whereas, haematological adverse events (AEs) occurred more frequent in the dasatinib group than in the imatinib group, the opposite is true for non-haematological AEs - except pleural effusions, these occurred only in dasatinib treated patients.
Despite these first encouraging interim results, further follow-up is essential to provide information on durability of the responses, quality-of- life and to further investigate the safety profile of dasatinib in the 1st-line therapy of CML.
|Item Type:||DSD: Horizon Scanning in Oncology|
|Additional Information:||This report is the product of a collaboration with the Agency for Health Technology Assessment in Poland (AHTAPol) and an offspring of the European network for Health Technology Assessment (EUnetHTA) Project that was supported by a grant from the European Commission. The responsibility lies with the author(s)solely, the European Commission is not responsible for any use that may be made of the information contained therein.|
|Keywords:||Leukemia, chronic myeloid leukemia, philadephia chromosome positive, chronic phase, CML, Ph+ CML-CP, dasatinib, sprycel|
|Subjects:||QZ Pathology > QZ 200-380 Neoplasms.Cysts|
WH Hemic and lymphatic systems
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
|Series Name:||DSD: Horizon Scanning in Oncology 17|
|Deposited on:||12 Apr 2011 17:37|
|Last Modified:||15 Apr 2011 12:29|
Repository Staff Only: item control page